Big news for anyone touched by lung cancer: the FDA just fully approved tarlatamab, a new immunotherapy that’s showing way better results than standard chemo for advanced small cell lung cancer. In a huge study, patients on tarlatamab lived longer and had fewer side effects—even those with brain metastases. Only 19% had to pause treatment, compared to 55% on chemo. This could be a real turning point for folks fighting this tough cancer! #Health #BodyHealth #LungCancer